4. Renal denervationOnce considered the next big thing for the medical device industry, renal denervation’s reputation took a hit in the middle of the 2010s when Medtronic announced a major clinical trial had failed to meet its efficacy endpoint. In other words, the study failed to prove that it effectively treated hypertension. The company, though, has since sought to clear up some of the confounding factors – namely, issues around differing medication regimens and patient compliance — that may have played a role in the Symplicity HTN-3 study’s failure.
Martha said this week that clinical trials have resumed for Symplicity Spyral renal denervation system.
“In our Om Med renal denervation trial, half of the sites have resumed enrollment, and we’re aiming to complete the trial and present the data next calendar year. We’re in the lead with Ardian, and this represents a multibillion-dollar opportunity to better treat the millions of patients around the world, who suffer from hypertension,” Martha said.